Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy
Safety and efficacy of vardenafil for the treatment of men with erectile dysfunction after radical retropubic prostatectomy
复制标题
DOI：
10.1097/01.ju.0000086947.00547.49
复制
发表时间：
2003-10-01
影响因子：
6.6
通讯作者：
Padma-Nathan, H
中科院分区：
文献类型：
--
作者：
Brock, G;Nehra, A;Padma-Nathan, H
目的：超过三分之一的男性在保留神经的根治性耻骨后前列腺切除术后可能会出现勃起功能障碍（ED）。伐地那非是一种有效的选择性磷酸二酯酶5抑制剂，用于根治性前列腺切除术后治疗ED的疗效和安全性。材料和方法：在这项双盲研究中，440名在保留神经的根治性前列腺切除术后发生ED的男性被随机分配服用安慰剂或10或20 mg伐地那非。12周后，使用国际勃起功能指数的勃起功能域，测量阴道插入和性交成功率的日记问题以及勃起的全球评估问题（GAQ）来测量疗效。结果：在治疗人群中，70%的人在基线时患有严重ED（勃起功能低于11）。12周后，两种伐地那非剂量均显著优于安慰剂(p
Purpose: More than one-third of men may experience erectile dysfunction (ED) after nerve sparing radical retropubic prostatectomy. The efficacy and safety of vardenafil, a potent, selective, phosphodiesterase 5 inhibitor, was assessed for the treatment of ED after radical prostatectomy.Materials and Methods: In this double-blind study 440 men with ED after nerve sparing radical prostatectomy were randomized to take placebo, or 10 or 20 mg vardenafil. Efficacy was measured after 12 weeks using the erectile function domain of the International Index of Erectile Function, diary questions measuring vaginal penetration and intercourse success rates, and a global assessment question (GAQ) on erection.Results: Of the intent to treat population 70% had severe ED (erectile function less than 11) at baseline. After 12 weeks both vardenafil doses were significantly superior to placebo (p